I want to tell you about an article I read years ago, before I was ever diagnosed, because the story it told has stayed with me and because I understand now what was being sold to me, and I did not understand then.

The article profiled a man who had been diagnosed with prostate cancer. He had been told to do conventional treatment. He declined. He moved to Italy, ate a Mediterranean diet full of fresh vegetables and olive oil and moderate red wine, lived what the article described as a slower and more beautiful life, and he lived another thirty years.

The story was presented as evidence that lifestyle changes could substitute for conventional cancer treatment. It was moving. I remember being moved by it. I filed it away in the back of my mind as an encouraging anecdote about the power of diet and place.

Years later, when I was researching for this series, I understood what the article had actually been saying — and what it had not been saying.

Prostate cancer is, in the majority of cases, a very slow-progressing cancer, particularly in older men. Many men diagnosed with localized prostate cancer will die with the cancer, not of the cancer. Some mainstream urological guidance for low-risk prostate cancer actually recommends active surveillance rather than immediate treatment, precisely because the cancer often progresses slowly enough that treatment side effects outweigh treatment benefits for certain patients. The man in the article was not an exception to oncology; in many presentations of prostate cancer, a man in his situation would have been expected to live a long time with or without aggressive treatment. Competing causes of mortality — heart disease, stroke, accident, other cancers — are statistically more likely to kill an older man with low-risk prostate cancer than the prostate cancer itself.

The article did not mention any of this. It presented a life expectancy that was roughly what mainstream oncology would have predicted, regardless of treatment choice, as if it were a triumph of alternative medicine. It took an outcome that was not actually anomalous and framed it as proof that the mainstream treatment he had been offered was unnecessary.

Then — and this is what I understood only much later — that framing was deployed in wellness content targeted at women with other cancers, most of which do not behave like low-risk prostate cancer at all. Breast cancer, for most stages and subtypes, progresses faster. Its outcomes are far more responsive to conventional treatment. Telling a newly diagnosed breast cancer patient the Italian salad story, as if it were a template she could follow, is telling her a story that was never about her.

The man in the article may have made the right call for himself. His case, stripped of the wellness framing, is not actually evidence of what the writers were trying to sell. And the people writing the wellness content were, almost certainly, not carefully walking through the biology of prostate cancer versus breast cancer versus lung cancer before they pointed that story at a vulnerable woman. They were pointing the story because it performed. They were doing it for the clicks.

Before we leave this ground, I want to name something that the post, as written so far, lets corporations off the hook for. It should not.

The individual wellness influencer who tells you to skip chemo is one shape of the problem. She is the most visible shape, because she is on your screen, looking you in the eye, holding a bottle. But the structural version of the same problem is running at a scale that dwarfs any individual account, and it is running from inside companies you already trust.

Consider the beverage conglomerate that sells green tea. Green tea, the legitimate product, contains antioxidants that are genuinely well-studied for their health effects — EGCG, the polyphenol that has real peer-reviewed evidence behind it for cardiovascular health, for metabolic markers, for certain aspects of cancer prevention and even for radiation dermatitis support in cancer patients. That is real science, and it is the science on which the marketing of green tea products is built. The image on the bottle is telling you a true story about the plant inside.

Now look at what is actually in the bottle.

The antioxidants in green tea are chemically fragile. They degrade over time, they degrade faster with heat, and they degrade faster still in the presence of light. A green tea beverage that has been bottled months ago, shipped across a country in trucks that get hot in summer, and sat on a warm store shelf under fluorescent light contains a fraction of the antioxidant content of fresh-brewed green tea. 

The company bottling and shipping it knows this. The food-science literature on polyphenol degradation is not obscure; it is the subject of doctoral theses and industrial white papers. A company selling a shelf-stable green tea product has access to better information about what is actually in their bottle than any consumer could produce on her own.

Now look at the container.

Most mass-market beverage bottles are made from plastics — polyethylene terephthalate and polycarbonates — that, under heat and time, leach compounds into the liquid they contain. Some of those compounds are classified as endocrine disruptors. The company shipping green tea in a plastic bottle through a hot logistics chain is, at scale, producing a product in which the antioxidant content has dropped and the endocrine-disrupting chemical content has risen. Again, this is not secret science. It is available in the same food-science literature any product team would consult.

Now look at the rest of the label. Most of these products are sweetened — often heavily, with either sugar or high-fructose corn syrup, at doses that make the beverage genuinely addictive in the dietary-psychology sense. The sweetness is doing the heavy lifting on repeat purchase. The green tea is doing the marketing.

Put all of that together and what you have is a product that is marketed on the truthful science of an ingredient it no longer meaningfully contains, packaged in a way that introduces compounds plausibly linked to the very diseases the ingredient is supposed to help prevent, sweetened to drive repeat purchase, and sold at volume to consumers who believe — because the label tells them — that they are making a health-supportive choice.

That is not a scroll-stopping Instagram reel. It is not a grifter with an affiliate link. It is a Fortune 500 company hitting its quarterly sales number by producing a dishonest product at industrial scale. And it is, in every way that matters, the same move. 

A vulnerable consumer is being sold something that is not what she was told it was, by a seller who has better information than she does, who profits from the gap between the representation and the reality.

None of this is illegal. It is all within current regulatory bounds. Regulatory bounds are not the relevant standard.

The relevant standard is whether the company knew, or should have known, that the product they were selling did not deliver what the marketing implied — and whether they sold it anyway because the numbers for the quarter mattered more than the honesty of the offer. When the answer to that is yes, that is unethical. It does not become less unethical because the company has a stock ticker and a marketing budget and a wellness-adjacent brand identity. It becomes more unethical, because the scale of harm is larger and the resources that could have been used to build an honest product were available and were not used.

I am not writing this to tell you to avoid all packaged beverages. I am writing it because the post has spent a lot of words being sharp toward the individual wellness influencer, and it would be dishonest to let large corporations off the hook for doing, at scale, a version of the same thing. A cancer patient who has been taught to be suspicious of the influencer telling her to skip chemo but not of the beverage company selling her degraded antioxidants in an EDC-leaching bottle has learned only half the lesson.

The question is the same question in both cases. What is being sold, and how does this seller profit from the gap between what the label says and what is actually in the thing? Apply that question to the Instagram reel. Apply it to the grocery store shelf. Apply it everywhere your money and your attention get asked for.

The grift is the pattern, not the size of the company running it.

One more piece of this argument, because it seals the whole case.

If a green tea beverage — or any over-the-counter food product, or any supplement, or any protocol, or any single ingredient — were actually a stand-alone cancer treatment at the efficacy the anti-chemo content suggests, the economics would not leave it on a grocery store shelf.

Consider the math of what is actually on offer. A single chemotherapy infusion for a common breast cancer regimen runs between fifteen and twenty-five thousand dollars. A full course of treatment — several infusions, plus radiation, plus years of endocrine therapy — regularly runs into the hundreds of thousands of dollars. The pharmaceutical industry spends tens of billions of dollars a year on cancer research. Pharmaceutical companies acquire, patent, and develop any molecule that shows real anticancer efficacy in clinical trials, because the market for an actually effective cancer treatment is, quite literally, measured in billions of dollars per drug per year.

Many of the chemotherapies in clinical use right now are derived from plants. Paclitaxel came from the Pacific yew tree. Vincristine came from the periwinkle plant. Etoposide came from the mayapple. Doxorubicin came from a soil fungus. The pharmaceutical industry is not ignoring plant compounds. It is systematically screening them, isolating the active molecules, concentrating them to doses that are biologically active, testing them in clinical trials, and bringing the ones that work to market. This is its business model. It is extremely good at it.

Which means: if green tea in its bottled beverage form were uniquely effective at treating cancer, it would not be sold as a beverage. It would be concentrated to pharmaceutical doses, administered as an infusion under medical supervision, patented by whatever company isolated and purified it, cost fifteen to twenty-five thousand dollars per dose, and be delivered in your oncologist's infusion suite alongside the other treatments she had recommended for you. It would not be three dollars at the checkout counter.

The fact that it is three dollars at the checkout counter is the market's own verdict on what is actually in the bottle. 

Markets are not always right about everything, but they are extremely reliable about one specific thing: the presence or absence of pharmaceutical-grade effect. Anything that actually cures cancer gets priced as the thing that actually cures cancer. The economic pressure to find and own such a compound is enormous, and nothing at pharmaceutical efficacy has ever hidden successfully on a grocery store shelf.

When a piece of content suggests otherwise — suggests that the cure is sitting in plain sight, rejected by medicine, available to you for the price of a grocery run — run that claim through this mechanic. Ask why, if the claim is true, the drug industry has not already patented the compound, concentrated it, and begun selling it for what the market would pay. The answer is almost always that the compound does not have the claimed effect, and the content making the claim is making it because the claim performs, not because it is true.

Which is the point at which it becomes important to say the opposite thing too, clearly, so that this entire argument does not accidentally condemn genuinely good things.

Green tea is good for you. Its polyphenols, notably EGCG, have real and well-documented benefits for cardiovascular health, metabolic markers, and inflammation, and there is credible preliminary evidence for topical EGCG in radiation dermatitis support. Drinking a high-quality brewed green tea — fresh leaves, properly steeped, not sitting in a plastic bottle in a hot warehouse for six months — is a good daily practice. It is not a silver bullet. It is not a substitute for chemotherapy. It is a modest daily good, and modest daily goods, stacked on top of each other across a lifetime, add up.

Turmeric is the same. Broccoli is the same. Olive oil, blueberries, wild salmon, walnuts, dark leafy greens, fresh citrus, whole grains, fermented foods, adequate protein, strength training, restorative sleep, sunlight exposure in the morning, social connection, meaningful work — these are all modest daily goods. They do not cure anything on their own. They compound, over years, into a body that is better equipped to do the harder work when the harder work arrives. 

Enjoy all of them. Build a life full of them. Just do not let anyone sell you one of them as a substitute for the treatment that actually does the harder work.

The real position is this: modest daily goods plus appropriate medical treatment is the complete picture. Neither half is optional. Neither half is sufficient on its own. And anyone selling you either half as the whole picture is either confused or profiting from the confusion.

If you want to add evidence-based complementary support to your treatment — and most women will want to, and most should — here is how to find it well.

Ask your oncologist or your cancer center whether they have an integrative oncology service, or whether they can refer you to one. If they do, use it. The services embedded within cancer centers are the gold standard because they are already coordinated with your oncology team.

If your center does not have one, look for practitioners who are either dual-credentialed (acupuncturists with specific oncology training, registered dietitians with oncology certification, physical therapists specializing in oncology) or who explicitly advertise that they work collaboratively with oncology teams and communicate with the primary treating physician. That last point matters. A legitimate integrative practitioner will send notes to your oncologist and expect your oncologist to send notes back. A red flag is a practitioner who does not want to coordinate with your oncology team, or who speaks disparagingly about your conventional treatment, or who frames herself as an alternative to what you are already doing.

Look for professionals whose recommendations track the Society for Integrative Oncology guidelines. Those guidelines are free to access online. You do not need to be a medical professional to read them.

Avoid anyone whose primary offering is protocols, supplements, or online coaching, and who makes money on affiliate commissions for those products. That business model is structurally predisposed to recommend more supplements and more protocols, regardless of what is best for you.

Avoid anyone who uses the word toxic to describe your chemotherapy while describing her own products as pure or clean. That framing is almost never medical. It is almost always marketing, and it is designed to turn your legitimate discomfort with chemotherapy's side effects into a conversion to her funnel.

And avoid anyone who tells you, flatly, that you do not need chemotherapy. Your oncologist is the only person in the world qualified to tell you whether you do or do not. A person who is not your oncologist and who makes that claim anyway is, almost by definition, someone to walk away from.

If you take nothing else from this post, take three questions. Any time a piece of content crosses your feed suggesting you skip, reduce, or replace your oncologist's recommendations, run it through these:

1. What is being sold? Look at the person's bio. Look at their link in bio. Look at what is in the background of their video. Look at the supplement brand they are tagged in. If the answer to how does this person make money is by telling me what they are telling me, that is a data point about why they are telling it to you.

2. What is the comparison? I healed naturally compared to what? If the answer is compared to a vague fear of what chemo would have done to me, that is not evidence of anything. That is the absence of evidence being sold as proof. Real evidence looks like outcomes data, matched cohorts, known biology of the specific cancer. It does not look like testimonials.

3. What would it cost you to bring this to your oncologist? Print the post. Screenshot the reel. Bring it to your next appointment. Ask her what she thinks. A good oncologist will engage with the question respectfully — she will tell you what is true in what you have read, what is false, and what is so context-dependent that it does not apply to you. A piece of advice that cannot survive that test is a piece of advice that should not be guiding life-or-death decisions about your body.

Three questions. You can apply them to any piece of content. They will not make the decision for you. They will give you the intellectual hygiene to make the decision yourself.

This post will not answer that question for you, because the specific answer to that specific question belongs to you and your oncologist. It belongs to the pathology of your cancer, the stage of your disease, the recommendations of your care team, and the reckoning you make about your own life and what you are willing to trade for what.

What I can tell you is this. If your oncologist has recommended chemotherapy for you, she is almost certainly recommending it because the math, specifically in your case, favors doing it. The math comes from decades of research on women like you, with cancers like yours, who either did or did not receive the treatment she is offering. Walking away from that offer is not empowerment. Walking away from that offer, in the cases where the math strongly favors treatment, is usually a decision that costs the woman who makes it her life.

Bring your questions. Bring your concerns. Bring your fear, which is real and valid and does not disqualify you from participating in your own decisions. Bring your salad and your supplements and your yoga and your clean skincare and your therapist, all of it, the full constellation of things that support a body through something hard. Bring all of it into collaboration with your oncology team. Do not let the algorithm, or the grift, or the snake oil, or the well-meaning wellness influencer with an affiliate link, talk you out of the treatment that is the most likely thing to keep you alive.

You were not diagnosed to become a patient. You were diagnosed with a problem that modern medicine is very good at solving, in most cases. The work in front of you is not whether to trust medicine. It is how to do the treatment well, come through it whole, and build the life on the other side.

We will walk that road with you, for the parts that are our expertise. Your oncologist will walk it with you for hers. Everything else — the salad, the skincare, the sleep, the movement — is yours, and it has always been yours, and you do not need anyone's permission to bring all of it with you.

I need to say this because it matters.

I built Juventude because I believe the skincare industry has failed women in specific, documentable ways — carrying ingredients linked to endocrine disruption, prioritizing profit over formulation, failing to do the research that women going through serious medical experiences need. That failure is real. I will continue to say it is real. That is what the brand is for.

But the failure of the skincare industry does not mean the failure of medicine. Those are two completely different arguments, and collapsing them is the move I will not make. 

The fact that a conventional beauty brand has been happy to sell you a moisturizer full of phthalates does not mean that your conventional oncologist is also failing you. She is almost certainly not. She is offering you the best of fifty years of research, aimed at the specific cancer in your specific body, and what she is offering is the thing that is most likely to save your life.

My position is simpler than it probably sounds at first. I distrust any seller — of products, of advice, of attention — who profits from the gap between what they are telling you and what is actually in the thing they are selling. 

The individual wellness influencer who sells you an anti-chemo narrative through her affiliate link is one version of this. 

The beverage corporation selling degraded green tea in an EDC-leaching bottle with enough sugar to make it addictive is another version. 

The skincare brand selling a moisturizer with EDCs in it, yet has a breast-cancer foundation fundraiser or pink-ribbon is another version. 

The grift is the pattern, not the size of the company running it, and I am suspicious of every version.

What I am not suspicious of is my oncologist. Not because medicine is perfect — it is not — but because my oncologist's professional success is measured in whether I am still alive. Her incentives point at my survival. That is not nothing. That is, structurally, more trustworthy than almost anything else being sold to me right now.

I did my chemotherapy. I did my radiation. I did my endocrine therapy. I would do all of it again. I also eat salads, use clean skincare, lift weights, practice mobility, sleep seven hours a night, and pay attention to what goes on and into my body. All of that fits together. None of it competes.

If any brand — including this one — ever tries to sell you a product as a substitute for something your oncologist has recommended, run from that brand. That is not us. That will never be us. We want you alive so you can buy our moisturizer for the rest of your long beautiful life. 

Because remember, traditional oncology works. Most people diagnosed and treated with cancer do live. The percent that live is increasing every year. There has never been more hope. And, when you are ready to stop focusing on surviving, and want to start thriving again- that's when we come in. 

Until then, know we're here cheering for you. Researching the interactions between bakuchiol and endocrine disruptors. Figuring out if you can use green tea after radiation. Telling you to stop retinol while doing chemo. We've got your back. 

Sincerely, 

Lindsey, CEO of Juventude | Breast Cancer Survivor | Patient Advocate 

References

1. American Cancer Society. Breast Cancer Facts & Figures 2023–2024. Accessed 2026. See also: Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2024. CA: A Cancer Journal for Clinicians 2024; 74(1): 12–49. ↩

2. Johnson SB, Park HS, Gross CP, Yu JB. Use of Alternative Medicine for Cancer and Its Impact on Survival. Journal of the National Cancer Institute 2018; 110(1): 121–124. ↩

3. Ayoade OF, et al. Use of Complementary and Alternative Medicine in the Management of Breast Cancer. JAMA Network Open 2026; published online March 2, 2026. ↩

4. Boffa DJ, quoted in Yale School of Medicine communications on the JAMA Network Open 2026 study. See: "Alternative Treatments are Linked to Lower Breast Cancer Survival," Yale School of Medicine, 2026. ↩

5. Society for Integrative Oncology. Clinical Practice Guidelines. Referenced via the National Institutes of Health National Center for Complementary and Integrative Health. Accessed 2026. ↩

6. Mao JJ, Pillai GG, Andrade CJ, et al. Integrative oncology: Addressing the global challenges of cancer prevention and treatment. CA: A Cancer Journal for Clinicians 2022; 72(2): 144–164. ↩

7. Deng GE, Rausch SM, Jones LW, et al. Complementary therapies and integrative medicine in lung cancer. Chest 2013; 143(5 Suppl): e420S–e436S. ↩